Cargando…

Better drugs for Lyme disease: focus on the spirochete

Twenty-five years ago, the AIDS epidemic was wreaking havoc around the world. Although “HIV denialists” threatened to undermine research efforts to combat the epidemic, development of targeted antiviral therapy eventually provided effective treatment for the disease. Now the Lyme disease epidemic is...

Descripción completa

Detalles Bibliográficos
Autores principales: Stricker, Raphael B, Middelveen, Marianne J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136917/
https://www.ncbi.nlm.nih.gov/pubmed/30237727
http://dx.doi.org/10.2147/IDR.S176831
_version_ 1783355091149914112
author Stricker, Raphael B
Middelveen, Marianne J
author_facet Stricker, Raphael B
Middelveen, Marianne J
author_sort Stricker, Raphael B
collection PubMed
description Twenty-five years ago, the AIDS epidemic was wreaking havoc around the world. Although “HIV denialists” threatened to undermine research efforts to combat the epidemic, development of targeted antiviral therapy eventually provided effective treatment for the disease. Now the Lyme disease epidemic is wreaking havoc around the world, and “Lyme denialists” are undermining efforts to combat the epidemic. Drawing on our experience with the AIDS epidemic, there is a significant need to develop targeted therapy to control the Lyme disease epidemic.
format Online
Article
Text
id pubmed-6136917
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61369172018-09-20 Better drugs for Lyme disease: focus on the spirochete Stricker, Raphael B Middelveen, Marianne J Infect Drug Resist Commentary Twenty-five years ago, the AIDS epidemic was wreaking havoc around the world. Although “HIV denialists” threatened to undermine research efforts to combat the epidemic, development of targeted antiviral therapy eventually provided effective treatment for the disease. Now the Lyme disease epidemic is wreaking havoc around the world, and “Lyme denialists” are undermining efforts to combat the epidemic. Drawing on our experience with the AIDS epidemic, there is a significant need to develop targeted therapy to control the Lyme disease epidemic. Dove Medical Press 2018-09-07 /pmc/articles/PMC6136917/ /pubmed/30237727 http://dx.doi.org/10.2147/IDR.S176831 Text en © 2018 Stricker and Middelveen. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Commentary
Stricker, Raphael B
Middelveen, Marianne J
Better drugs for Lyme disease: focus on the spirochete
title Better drugs for Lyme disease: focus on the spirochete
title_full Better drugs for Lyme disease: focus on the spirochete
title_fullStr Better drugs for Lyme disease: focus on the spirochete
title_full_unstemmed Better drugs for Lyme disease: focus on the spirochete
title_short Better drugs for Lyme disease: focus on the spirochete
title_sort better drugs for lyme disease: focus on the spirochete
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136917/
https://www.ncbi.nlm.nih.gov/pubmed/30237727
http://dx.doi.org/10.2147/IDR.S176831
work_keys_str_mv AT strickerraphaelb betterdrugsforlymediseasefocusonthespirochete
AT middelveenmariannej betterdrugsforlymediseasefocusonthespirochete